LivaNova (NASDAQ:LIVN) Receives "Buy" Rating from Needham & Company LLC

LivaNova (NASDAQ:LIVN - Get Free Report)'s stock had its "buy" rating reaffirmed by analysts at Needham & Company LLC in a note issued to investors on Tuesday,Benzinga reports. They presently have a $75.00 target price on the stock. Needham & Company LLC's target price would indicate a potential upside of 48.43% from the stock's previous close.

Several other equities analysts also recently commented on LIVN. Mizuho cut their price target on shares of LivaNova from $80.00 to $70.00 and set an "outperform" rating on the stock in a report on Thursday, October 31st. StockNews.com downgraded LivaNova from a "strong-buy" rating to a "buy" rating in a report on Thursday, January 23rd. The Goldman Sachs Group assumed coverage on LivaNova in a research report on Friday, October 4th. They issued a "buy" rating and a $65.00 price objective on the stock. Finally, Robert W. Baird lifted their target price on LivaNova from $66.00 to $72.00 and gave the stock an "outperform" rating in a research report on Thursday, October 31st. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $69.17.

LivaNova Price Performance

LIVN traded up $1.00 during trading hours on Tuesday, hitting $50.53. The company's stock had a trading volume of 612,180 shares, compared to its average volume of 496,775. The stock has a market cap of $2.74 billion, a price-to-earnings ratio of 120.31 and a beta of 1.01. The business's 50-day moving average price is $49.05 and its 200-day moving average price is $49.97. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46. LivaNova has a 12 month low of $43.15 and a 12 month high of $64.47.

Insider Activity

In other LivaNova news, Director Francesco Bianchi sold 1,250 shares of the company's stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $50.99, for a total transaction of $63,737.50. Following the completion of the sale, the director now owns 7,522 shares in the company, valued at $383,546.78. This represents a 14.25 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.27% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the company. Nordea Investment Management AB increased its position in LivaNova by 22.2% during the 4th quarter. Nordea Investment Management AB now owns 68,711 shares of the company's stock valued at $3,188,000 after buying an additional 12,470 shares in the last quarter. Harbor Capital Advisors Inc. purchased a new stake in shares of LivaNova during the fourth quarter worth about $1,954,000. Allspring Global Investments Holdings LLC increased its holdings in shares of LivaNova by 3.3% during the third quarter. Allspring Global Investments Holdings LLC now owns 797,284 shares of the company's stock valued at $41,889,000 after acquiring an additional 25,277 shares in the last quarter. State of New Jersey Common Pension Fund D raised its position in shares of LivaNova by 38.3% in the 3rd quarter. State of New Jersey Common Pension Fund D now owns 42,539 shares of the company's stock valued at $2,235,000 after purchasing an additional 11,782 shares during the last quarter. Finally, Entropy Technologies LP acquired a new stake in LivaNova in the 3rd quarter worth approximately $529,000. Hedge funds and other institutional investors own 97.64% of the company's stock.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.